Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Stem Cell Educator Therapy · 1 trial · 1 indication
The primary study endpoint will be the occurrence of treatment-related adverse effects. Adverse events that occur during therapy (especially those that necessitate temporary or permanent discontinuation of therapy) and over the 12-month follow-up period will be assessed.
| Arm | Type | Description |
|---|---|---|
| Stem Cell Educator Therapy | EXPERIMENTAL | Patients will have apheresis performed and then have their own blood returned to them with the "educated" lymphocytes |
| Name | Type | Description |
|---|---|---|
| Stem Cell Educator Therapy | BIOLOGICAL | Patients will receive apheresis and then have their own blood returned to them with the "educated" lymphocytes |
Inclusion Criteria: * Adult patients \>/=18 years * Must have a diagnosis of type 1 diabetes mellitus based on the 2015 American Diabetes Association criteria for the Clarification and Diagnosis of diabetes * Must have a blood test confirming the presence of at least one autoantibody to pancreatic ...
Stem Cell Educator Therapy is an investigational therapy being studied for the treatment of Diabetes Mellitus Type 1. It is currently in Phase 1 clinical development and has not been approved by the FDA. The therapy is intended to address the underlying autoimmune process in type 1 diabetes.
Stem Cell Educator Therapy is being developed by Meridian Bioscience Inc, which trades under the ticker VIVO. The company is conducting clinical research to evaluate the therapy's potential in treating type 1 diabetes.
Stem Cell Educator Therapy is in Phase 1 clinical development. It is an investigational therapy and has not received FDA approval. The therapy is being studied for its safety and potential efficacy in patients with type 1 diabetes.
Stem Cell Educator Therapy has one completed clinical trial, identified as NCT02624804. This Phase 1 study, titled 'A Pilot Study of the Therapeutic Potential of Stem Cell Educator Therapy in Type 1 Diabetes,' enrolled 13 participants in the United States. The trial was uncontrolled and not randomized.
Yes, Stem Cell Educator Therapy is classified as a monoclonal antibody modality. It is being investigated as a potential treatment for type 1 diabetes, with a focus on modulating the immune system to address the disease.